A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Registration Number
- NCT01774786
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line treatment in participants with HER2-positive metastatic gastroesophageal junction (GEJ) or gastric cancer (GC). Participants will be randomized to receive pertuzumab 840 milligrams (mg) or placebo intravenously every 3 weeks (q3w) in combination with trastuzumab (initial dose of 8 milligrams per kilogram \[mg/kg\] intravenously \[IV\] followed by 6 mg/kg IV q3w) and cisplatin and fluoropyrimidine (capecitabine or 5-fluorouracil) for the first 6 treatment cycles. Participants will continue to receive pertuzumab or placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 780
- Histologically confirmed metastatic adenocarcinoma of the stomach or GEJ
- Measurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Life expectancy greater than equal to (>/=) 3 months
- Previous cytotoxic chemotherapy for advanced (metastatic) disease
- Evidence of disease progression documented within 6 months after completion of prior neoadjuvant or adjuvant cytotoxic chemotherapy, or both, or radiotherapy for GEJ adenocarcinoma
- Previous treatment with any HER2-directed therapy, at any time, for any duration
- Previous exposure to any investigational treatment within 30 days before the first dose of study treatment
- Radiotherapy within 30 days before the first dose of study treatment (within 2 weeks if given as palliation to bone metastases, if recovered from all toxicities)
- History or evidence of brain metastases
- Clinically significant active gastrointestinal (GI) bleeding (Grade >/=2 according to National Cancer Institute [NIC]-Common Terminology Criteria for Adverse Events Version 4.0 [CTCAEv.4.0])
- Residual toxicity resulting from previous therapy (for example, hematologic, cardiovascular, or neurologic toxicity that is Grade >/=2). Alopecia is permitted
- Other malignancy (in addition to gastric cancer [GC]) within 5 years before enrollment, except for carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin that has been previously treated with curative intent
- Inadequate hematologic, renal or liver function
- Pregnant or lactating women
- History of congestive heart failure of any New York Heart Association (NYHA) criteria
- Angina pectoris requiring treatment
- Myocardial infarction within the past 6 months before the first dose of study drug
- Clinically significant valvular heart disease or uncontrollable high-risk cardiac arrhythmia
- History or evidence of poorly controlled hypertension
- Baseline left ventricular ejection fraction (LVEF) value less than (<) 55 percent (%)
- Any significant uncontrolled intercurrent systemic illness
- Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo + Trastuzumab + Chemotherapy Placebo Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Pertuzumab + Trastuzumab + Chemotherapy Capecitabine Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Pertuzumab + Trastuzumab + Chemotherapy 5-Fluorouracil Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Pertuzumab + Trastuzumab + Chemotherapy Cisplatin Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Pertuzumab + Trastuzumab + Chemotherapy Pertuzumab Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Pertuzumab + Trastuzumab + Chemotherapy Trastuzumab Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Placebo + Trastuzumab + Chemotherapy Cisplatin Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Placebo + Trastuzumab + Chemotherapy 5-Fluorouracil Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Placebo + Trastuzumab + Chemotherapy Capecitabine Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason. Placebo + Trastuzumab + Chemotherapy Trastuzumab Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
- Primary Outcome Measures
Name Time Method Overall Survival From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months) Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day.
- Secondary Outcome Measures
Name Time Method Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months) Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions.
Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months) The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months) The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months) Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan.
Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months) The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis.
Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03 From Baseline until end of post-treatment follow-up (up to 70 months) An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD) From Baseline until end of post-treatment follow-up (up to 70 months) The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years) The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years) The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
Maximum Serum Concentration (Cmax) of Pertuzumab Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days) Cmax of Trastuzumab Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days) Minimum Serum Concentration (Cmin) of Pertuzumab Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days) Cmin of Trastuzumab Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)
Trial Locations
- Locations (172)
Florida Cancer Specialists - SCRI; Pharmacy
🇺🇸Fort Myers, Florida, United States
Weill Medical College of Cornell University; Division of Hematology & Medical Oncology
🇺🇸New York, New York, United States
University Of Chicago Medical Center; Section Of Hematology/Oncology
🇺🇸Chicago, Illinois, United States
Comprehensive Cancer Centers of Nevada - Eastern Avenue
🇺🇸Las Vegas, Nevada, United States
Indiana University Health; Goshen Center for Cancer Care
🇺🇸Goshen, Indiana, United States
New York Oncology Hematology, P.C.
🇺🇸Albany, New York, United States
Queens Medical Associates
🇺🇸Fresh Meadows, New York, United States
Oncology Hematology Care
🇺🇸Cincinnati, Ohio, United States
Royal Brisbane Womens Hosp; Division of Oncology
🇦🇺Herston, Queensland, Australia
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
🇦🇹Salzburg, Austria
Krankenhaus St. Vinzenz Der Barmherzigen Schwestern Zams; Abt. Für Innere Medizin
🇦🇹Zams, Austria
Clinicas Oncologicas Integradas - COI
🇧🇷Rio De Janeiro, RJ, Brazil
Centro de Pesquisas Oncologicas - CEPON
🇧🇷Florianopolis, SC, Brazil
Hospital A. C. Camargo; Oncologia
🇧🇷Sao Paulo, SP, Brazil
Hospital Nossa Senhora da Conceicao
🇧🇷Porto Alegre, RS, Brazil
Universidade Federal de Sao Paulo - UNIFESP*X
🇧🇷Sao Paulo, SP, Brazil
Complex Oncological Center - Plovdiv, EOOD
🇧🇬Plovdiv, Bulgaria
MHAT Serdika
🇧🇬Sofia, Bulgaria
SHATOD Dr. Marko Antonov Markov-Varna, EOOD; Department of Medicinall Onchotherapy and Palliative
🇧🇬Varna, Bulgaria
Hamilton Health Sciences - Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
Health Sciences North
🇨🇦Sudbury, Ontario, Canada
Toronto East General Hospital; Haematology/Oncology
🇨🇦Toronto, Ontario, Canada
Sunnybrook Health Science Centre
🇨🇦Toronto, Ontario, Canada
McGill University; Glen Site; Oncology
🇨🇦Montreal, Quebec, Canada
Cancer Hospital Chinese Academy of Medical Sciences.
🇨🇳Beijing, China
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
the First Hospital of Jilin University
🇨🇳Changchun, China
Jilin Cancer Hospital
🇨🇳Changchun, China
Sun Yet-sen University Cancer Center
🇨🇳Guangzhou, China
Changzhou First People's Hospital
🇨🇳Changzhou, China
Third Affiliated Hospital of Third Military Medical University
🇨🇳ChongQing, China
Fuzhou General Hospital, PLA Nanjing Military Area Command
🇨🇳Fuzhou, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
🇨🇳Hangzhou, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
The 1st Affiliated Hospital of Nanchang Unversity
🇨🇳Nanchang, China
Zhongshan Hospital Fudan University
🇨🇳Shanghai, China
Affiliated Hospital of Nantong University
🇨🇳Nantong, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
General Hospital of Shenyang Military Command of PLA
🇨🇳Shenyang, China
Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)
🇨🇳Shijiazhuang, China
The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)
🇨🇳Xi'an, China
The Affiliated Hospital of Xuzhou Medical College
🇨🇳Xuzhou, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, China
Clinical Hospital Sisters of Mercy
🇭🇷Zagreb, Croatia
Clinical Hospital Centre Zagreb
🇭🇷Zagreb, Croatia
Docrates Cance Center
🇫🇮Helsinki, Finland
Turku Uni Central Hospital; Oncology Clinics
🇫🇮Turku, Finland
Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung
🇩🇪Essen, Germany
Klinik Esslingen; Klinik für Allgemeine Innere Medizin, Onkologie/Haematologie
🇩🇪Esslingen, Germany
Universitätsklinikum Hamburg-Eppendorf; Hubertus Wald Tumorzentrum
🇩🇪Hamburg, Germany
Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie
🇩🇪Essen, Germany
Klinikum Ludwigsburg; Studiensekretariat
🇩🇪Ludwigsburg, Germany
Universitätsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin I
🇩🇪Ulm, Germany
Semmelweis Egyetem Onkologiai Központ
🇭🇺Budapest, Hungary
Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika
🇭🇺Debrecen, Hungary
Seconda Universita' Degli Studi; Divsione Di Oncologia Medica
🇮🇹Napoli, Campania, Italy
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
🇮🇹Bologna, Emilia-Romagna, Italy
Ospedali Riuniti Di Ancona; Oncology
🇮🇹Ancona, Marche, Italy
Ospedale Casa Sollievo Della Sofferenza IRCCS
🇮🇹San Giovanni Rotondo, Puglia, Italy
Ospedale Misericordia E Dolce; Oncologia Medica
🇮🇹Prato, Toscana, Italy
Nagoya university Hospital; Gastroenterological Surgery 2
🇯🇵Aichi, Japan
National Hospital Organization Shikoku Cancer Center; Gastroenterology
🇯🇵Ehime, Japan
Kyushu University Hospital; Surgery and Science
🇯🇵Fukuoka, Japan
Hiroshima City Hiroshima Citizens Hospital; Surgery
🇯🇵Hiroshima, Japan
St.Marianna University School of Medicine hospital; Medical Oncology
🇯🇵Kanagawa, Japan
Osaka International Cancer Institute;; Medical oncology and Gastrointestinal oncology
🇯🇵Osaka, Japan
Osaka General Medical Center; Gastroenterological Surgery
🇯🇵Osaka, Japan
Kyungpook National University Medical Center
🇰🇷Daegu, Korea, Republic of
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
Seoul St Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Universiti Sains Malaysia [Neurology]
🇲🇾Kubang Kerian, Kelantan, Malaysia
Hospital Kuala Lumpur; Jabatan Radioterapi dan Onkologi
🇲🇾Kuala Lumpur, Malaysia
Hospital Wanita dan Kanak-Kanak Sabah
🇲🇾Sabah, Malaysia
Inst. Nacional de Cancerologia; Investigacion Clinica
🇲🇽Mexico City, Mexico
Clinical Hospital; Oncology Department
🇲🇰Bitola, North Macedonia
University Clinic for Radiotherapy and Oncology
🇲🇰Skopje, North Macedonia
Centro Medico Monte Carmelo
🇵🇪Arequipa, Peru
Hospital Sabogal; Oncology
🇵🇪Callao, Peru
Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional
🇵🇪Lima, Peru
Hosp Nacion Edgardo Rebagliati; Oncologia Medica
🇵🇪Jesus Maria, Peru
Clinica San Borja
🇵🇪Lima, Peru
Wojewódzki Szpital Specjalistyczny Nr 3
🇵🇱Rybnik, Poland
Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii
🇵🇱Bydgoszcz, Poland
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Klinika Gastroenterologii Onkologicznej
🇵🇱Warszawa, Poland
Euroclinic Center of Oncology SRL
🇷🇴Iasi, Romania
Oncology Center Sf. Nectarie
🇷🇴Craiova, Romania
Hospital General Universitario de Elche; Servicio de Oncologia
🇪🇸Elche, Alicante, Spain
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸Córdoba, Cordoba, Spain
Hospital del Mar; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital Duran i Reynals; Oncologia
🇪🇸Barcelona, Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸Barcelona, Spain
CHUV; Departement d'Oncologie
🇨🇭Lausanne, Switzerland
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Taichung Veterans General Hospital; Dept of Surgery
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital; Oncology
🇨🇳Tainan, Taiwan
National Taiwan Uni Hospital; Dept of Oncology
🇨🇳Taipei, Taiwan
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
🇹🇭Bangkok, Thailand
Khonkaen Hospital
🇹🇭Khonkaen, Thailand
Songklanagarind Hospital; Department of Oncology
🇹🇭Songkhla, Thailand
Asst Papa Giovanni XXIII; Oncologia Medica
🇮🇹Bergamo, Lombardia, Italy
Kanagawa Cancer Center; Gastrointestinal Surgery
🇯🇵Kanagawa, Japan
National Cancer Center Hospital; Gastrointestinal Oncology
🇯🇵Tokyo, Japan
Medical Research Centre
🇵🇦Panama, Panama
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
🇵🇱Kraków, Poland
Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department
🇹🇷Erzurum, Turkey
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
National Cancer Center Hospital East; Gastroenterology
🇯🇵Chiba, Japan
Kobe city Medical center General Hospital; Medical Oncology
🇯🇵Hyogo, Japan
University Malaya Medical Centre; Clinical Oncology Unit,
🇲🇾Kuala Lumpur, Malaysia
Hospital Angeles Metropolitano; Room 220
🇲🇽Mexico City, Mexico CITY (federal District), Mexico
Oaxaca Site Management Organization
🇲🇽Oaxaca, Mexico
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
🇷🇺Samara, Russian Federation
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
🇹🇭Bangkok, Thailand
Asan Medical Center; Medical Oncology
🇰🇷Seoul, Korea, Republic of
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Tennessee Oncology PLLC - Nashville (20th Ave)
🇺🇸Nashville, Tennessee, United States
Monash Medical Centre; Oncology
🇦🇺Clayton, Victoria, Australia
Austin Health; Cancer Clinical Trial Centre
🇦🇺Heidelberg, Victoria, Australia
Mount Sinai Hospital; Oncology
🇨🇦Toronto, Ontario, Canada
Hospital Sirio Libanes; Centro de Oncologia
🇧🇷Sao Paulo, SP, Brazil
Clinica de Oncologia Medica
🇧🇷Sao Paulo, SP, Brazil
Universitaetsklinikum Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)
🇩🇪Leipzig, Germany
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz;Sugarterapias Klinikai Onkologiai Intez
🇭🇺Miskolc, Hungary
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
🇭🇺Szeged, Hungary
Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
🇩🇪Berlin, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz; II. Medizinische Klinik
🇩🇪Mainz, Germany
Philipps-Universität Marburg; Klinik für Innere Med.; Schwerpunkt Hämatologie/Onkologie/Immunologie
🇩🇪Marburg, Germany
London Regional Cancer Centre
🇨🇦London, Ontario, Canada
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
🇭🇺Budapest, Hungary
Universitätsklinikum Mannheim, Tagestherapiezentrum, Interdisziplinäres Tumorzentrum
🇩🇪Mannheim, Germany
Medical Solution; Hematology
🇬🇹Guatemala, Guatemala
Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
🇮🇹Milano, Lombardia, Italy
Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2
🇮🇹Pisa, Toscana, Italy
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Yonsei Medical Center; Dept. of Medicine , Division of Hemato-Oncology
🇰🇷Seoul, Korea, Republic of
AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia
🇮🇹Reggio Emilia, Emilia-Romagna, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Lazio, Italy
Toyama University Hospital;Gastroenterology and Hematology
🇯🇵Toyama, Japan
Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department
🇰🇿Almaty, Kazakhstan
NZOZ Centrum Medyczne HCP Sp. z o.o.
🇵🇱Poznan, Poland
Taipei Veterans General Hospital
🇨🇳Taipei City, Taiwan
Ankara Uni School of Medicine; Medical Oncology
🇹🇷Ankara, Turkey
Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department
🇹🇷Edirne, Turkey
Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology
🇹🇷Istanbul, Turkey
Irccs Ospedale San Raffaele
🇮🇹Milano, Lombardia, Italy
Aichi Cancer Center Hospital; Clinical Oncology
🇯🇵Aichi, Japan
Saitama Cancer Center; Gastroenterology
🇯🇵Saitama, Japan
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
🇷🇺Kazan, Russian Federation
SBI for HPE "Ryazan State Medical University n.a. I.P. Pavlov" of MoH of RF
🇷🇺Ryazan, Russian Federation
Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology
🇨🇳Taoyuan, Taiwan
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
🇪🇸Badalona, Barcelona, Spain
Academisch Medisch Centrum Universiteit Amsterdam
🇳🇱Amsterdam, Netherlands
Bialostockie Ctr Onkologii; Oddzial Chemioterapii Dziennej
🇵🇱Bialystok, Poland
Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny
🇵🇱Brzozów, Poland
SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarawskiego
🇵🇱Opole, Poland
Cardiomed Medical Center
🇷🇴Cluj-Napoca, Romania
Clinical Oncology Dispensary; Chemotherapy
🇷🇺Omsk, Russian Federation
Luzerner Kantonsspital; Medizinische Onkologie
🇨🇭Luzern, Switzerland
Rajavithi Hospital; Division of Medical Oncology
🇹🇭Bangkok, Thailand
Akdeniz University Medical Faculty; Medical Oncology Department
🇹🇷Antalya, Turkey
Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department
🇹🇷Malatya, Turkey
TC Necmettin Erbakan University Meram Medical Faculty Hospital
🇹🇷Konya, Turkey
Sir Charles Gairdner Hospital; Medical Oncology
🇦🇺Perth, Western Australia, Australia
Hospital Oncologia; Oncology
🇸🇻Salvador, El Salvador
The 81st Hospital of P.L.A.
🇨🇳Nanjing City, China
Gifu University Hospital; Digestive Surgery
🇯🇵Gifu, Japan
Medical University of South Carolina; Hollings Cancer Center
🇺🇸Charleston, South Carolina, United States